Because of the prevalent overexpression of NAD(P)H: quinone oxidoreductase isozyme 1 (NQO1) in many cancer types, an NQO1-responsive version of CyNH2, named NCyNH2, was developed to improve the specificity for targeting tumor cells. This evidence concerns the gene NQO1 and cancer.